This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ridolfi, R. Articles by Nanni, O. Search for Related Content PubMed PubMed Citation Articles by Ridolfi, R. Articles by Nanni, O. Social Bookmarking                            What's this?

Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial

From the Department of Medical Oncology, Pierantoni Hospital, Forlì; Department of Medical Oncology, Busonera Hospital, Padua; Department of Medical Oncology, Oncology Institute of Bari, Bari; Medical Oncology Unit, S. Chiara Hospital, Pisa; Department of Radiotherapy and Oncology, Riuniti Hospital, Bergamo; Aviano Cancer Institute, Aviano; Oncology Unit, S. Maria degli Angeli Hospital, Pordenone; Department of Medical Oncology, Maggiore Hospital, Verona; Oncology Center, S. Chiara Hospital, Trento; and Istituto Oncologico Romagnolo, Forlì, Italy.

Address reprint requests to Ruggero Ridolfi, MD, Department of Medical Oncology, Pierantoni Hospital, Via Forlanini, 34, 47100 Forlì, Italy; email: i.o.r{at}fo.nettuno.it

PURPOSE: Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alfa-2b (IFN-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS). Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting. We conducted a multicenter prospective randomized clinical trial in outpatients with metastatic melanoma to compare CT with biochemotherapy (bioCT) using immunomodulant doses of IL-2 and IFN-2b.

PATIENTS AND METHODS: One hundred seventy-six eligible patients with advanced melanoma were randomized to receive CT (cisplatin and dacarbazine with or without carmustine every 21 days) or bioCT comprising the same CT regimen followed by low-dose subcutaneous IL-2 for 8 days and IFN2b three times a week, both for six cycles.

RESULTS: At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P = .51), respectively. In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria. In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P = .70) were recorded. Treatment-related toxicity was fairly similar in both arms.

CONCLUSION: The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR. However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2–containing regimens reported in the literature. Furthermore, our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. A. Trinh Current management of metastatic melanoma Am. J. Health Syst. Pharm., December 15, 2008; 65(24_Supplement_9): S3 - S8. [Abstract] [Full Text] [PDF]

				M. B. Atkins, J. Hsu, S. Lee, G. I. Cohen, L. E. Flaherty, J. A. Sosman, V. K. Sondak, and J. M. Kirkwood Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group J. Clin. Oncol., December 10, 2008; 26(35): 5748 - 5754. [Abstract] [Full Text] [PDF]

				N. J. Ives, R. L. Stowe, P. Lorigan, and K. Wheatley Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients J. Clin. Oncol., December 1, 2007; 25(34): 5426 - 5434. [Abstract] [Full Text] [PDF]

				D. F. McDermott and M. B. Atkins More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma J. Clin. Oncol., September 1, 2007; 25(25): 3791 - 3793. [Full Text] [PDF]

				M. A. Hofmann, W. Sterry, and U. Trefzer Complex Combination Biochemotherapy Regimen in Advanced Metastatic Melanoma in a Non-intensive Care Unit: Toxicity or Benefit? Jpn. J. Clin. Oncol., March 1, 2007; 37(3): 224 - 229. [Abstract] [Full Text] [PDF]

				P Del Bianco and R Borgoni Handling dropout and clustering in longitudinal multicentre clinical trials Statistical Modeling, July 1, 2006; 6(2): 141 - 157. [Abstract] [PDF]

				E. Bajetta, M. Del Vecchio, P. Nova, A. Fusi, A. Daponte, M. R. Sertoli, P. Queirolo, P. Taveggia, M. G. Bernengo, S. S. Legha, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-{alpha}2b in metastatic melanoma Ann. Onc., April 1, 2006; 17(4): 571 - 577. [Abstract] [Full Text] [PDF]

				U. Keilholz, C. J.A. Punt, M. Gore, W. Kruit, P. Patel, D. Lienard, J. Thomas, T. M. Proebstle, A. Schmittel, D. Schadendorf, et al. Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group J. Clin. Oncol., September 20, 2005; 23(27): 6747 - 6755. [Abstract] [Full Text] [PDF]

				Y. Fernandez, M. Verhaegen, T. P. Miller, J. L. Rush, P. Steiner, A. W. Opipari Jr., S. W. Lowe, and M. S. Soengas Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications Cancer Res., July 15, 2005; 65(14): 6294 - 6304. [Abstract] [Full Text] [PDF]

				K. Spanknebel, K. Y. Cheung, J. Stoutenburg, K. Hurst-Wicker, C. Hesdorffer, G. DeRaffele, and H. L. Kaufman Initial Clinical Response Predicts Outcome and Is Associated With Dose Schedule in Metastatic Melanoma and Renal Cell Carcinoma Patients Treated With High-Dose Interleukin 2 Ann. Surg. Oncol., May 1, 2005; 12(5): 381 - 390. [Abstract] [Full Text] [PDF]

				J. Koduri, M. A. Baumann, R. Ridolfi, and O. Nanni Cisplatin and Dacarbazine With or Without Subcutaneous Interleukin-2 and Interferon Alfa-2b in Advanced Melanoma Outpatients J. Clin. Oncol., August 15, 2002; 20(16): 3560 - 3561. [Full Text] [PDF]